EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Use of Ceftazidime-Avibactam in Children Admitted to Pediatric Intensive Care Units

André Ricardo Araujo da Silva, Rafael Quijada

Children · 29.05.2024 · 11 (6) · 664

DOI: 10.3390/children11060664 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Children, online erschienen am 29.05.2024. Verfasst von André Ricardo Araujo da Silva und 1 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Universidade Federal Fluminense, Niterói 24220-900, Brazil. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Ceftazidime-Avibactam (CAZ-AVI) is one of the new antibiotics available to treat infections due to carbapenem-resistant gram-negative bacteria (CRB). Our aim was to describe the use of CAZ-AVI in children admitted to pediatric intensive care units (PICUs), with suspected or proven CRB infections.

Methods

A retrospective descriptive study was conducted in two PICUs of Rio de Janeiro, Brazil, between January 2020 and January 2024. Children aged 0 to 18 years who received CAZ-AVI for more than 24 h were included.

Results

CAZ-AVI was used in 37 patients. The median age was 28 months (range 1–215), 17 (45.9%) being male. The median time from the patient admission to the initial prescription of CAZ-AVI was 39.9 days (range 1–138). Thirty-four (91.9%) children had at least one comorbidity at admission and (91.9%) used at least one invasive device prior to the CAZ-AVI prescription, and 89.2% had received carbapenem before; and fifteen (40.5%) had healthcare-associated infection (HAI) prior to CAZ-AVI use. The mean time of CAZ-AVI use was 11 days (range 1–22). Gram-negative bacteria were isolated in cultures from 12 (32.4%) patients in the 24 h prior to prescription or on the day of prescription. In five patients, CRB was confirmed in cultures, and in four (80%) of them, microbiological clearance was verified after 7 days of treatment. The 30-day mortality rate was 37.8%.

Conclusion

Almost all patients who used CAZ-AVI were critically ill children with multiple comorbidities and previous use of carbapenems. Among CRB confirmed infections, microbiology clearance in 7 days was high.

Schlagwörter

Stichwörter der Autor:innen

ceftazidime-avibactampediatric intensive care unittreatment

Autor:innen und Institutionen

  • Faculty of Medicine, Universidade Federal Fluminense, Niterói 24220-900, Brazil.
  • Prontobaby Group, Rio de Janeiro 20540-100, Brazil.

Zitieren

APA

Araujo da Silva, A. R., & Quijada, R. (2024). Use of Ceftazidime-Avibactam in Children Admitted to Pediatric Intensive Care Units. Children, 11(6), 664. https://doi.org/10.3390/children11060664

Vancouver

Araujo da Silva AR, Quijada R. Use of Ceftazidime-Avibactam in Children Admitted to Pediatric Intensive Care Units. Children. 2024;11(6):664. doi:10.3390/children11060664

BibTeX
@article{AraujodaSilva2024,
  author = {Araujo da Silva, André Ricardo and Quijada, Rafael},
  title = {Use of Ceftazidime-Avibactam in Children Admitted to Pediatric Intensive Care Units},
  journal = {Children},
  year = {2024},
  volume = {11},
  number = {6},
  pages = {664},
  doi = {10.3390/children11060664}
}
Kostenlos starten →